First, broad inhibition of STAT3 via administration of the STAT3-specific inhibitor, LLL-12, markedly improved multiple histological, biochemical, physiological, and functional endpoints in a mouse model of amyloidosis. The gene discussed is STAT3; the disease is amyloidosis.